JOP20250053A1 - البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد - Google Patents

البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد

Info

Publication number
JOP20250053A1
JOP20250053A1 JOJO/P/2025/0053A JOP20250053A JOP20250053A1 JO P20250053 A1 JOP20250053 A1 JO P20250053A1 JO P20250053 A JOP20250053 A JO P20250053A JO P20250053 A1 JOP20250053 A1 JO P20250053A1
Authority
JO
Jordan
Prior art keywords
piperidine
methyl
gallic acid
nicotinamide
pyrazolpyridine
Prior art date
Application number
JOJO/P/2025/0053A
Other languages
Arabic (ar)
English (en)
Inventor
Jeffrey A Peterson
David Andrew Coates
Gislaine Kuminek
Lori Raquel Hilden
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20250053A1 publication Critical patent/JOP20250053A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2025/0053A 2022-09-07 2025-03-06 البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد JOP20250053A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
JOP20250053A1 true JOP20250053A1 (ar) 2025-03-06

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0053A JOP20250053A1 (ar) 2022-09-07 2025-03-06 البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد

Country Status (18)

Country Link
US (1) US12662483B2 (cg-RX-API-DMAC7.html)
EP (1) EP4584270A1 (cg-RX-API-DMAC7.html)
JP (2) JP7541606B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250057022A (cg-RX-API-DMAC7.html)
CN (1) CN120187720A (cg-RX-API-DMAC7.html)
AR (1) AR130417A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023338199B2 (cg-RX-API-DMAC7.html)
CA (1) CA3266872A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025002467A2 (cg-RX-API-DMAC7.html)
CR (1) CR20250077A (cg-RX-API-DMAC7.html)
DO (1) DOP2025000054A (cg-RX-API-DMAC7.html)
IL (1) IL319342A (cg-RX-API-DMAC7.html)
JO (1) JOP20250053A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025002687A (cg-RX-API-DMAC7.html)
PE (1) PE20251400A1 (cg-RX-API-DMAC7.html)
TW (1) TWI862146B (cg-RX-API-DMAC7.html)
WO (1) WO2024054814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途
WO2026084690A1 (en) * 2024-10-14 2026-04-23 Eli Lilly And Company Fgfr3 inhibitor dosing regimens for use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163790B2 (en) * 2005-12-08 2012-04-24 New Form Pharmaceuticals, Inc. Metronidazole cocrystals and imipramine cocrystals
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技(苏州)有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
DOP2025000054A (es) 2025-03-31
AU2023338199A1 (en) 2025-03-20
EP4584270A1 (en) 2025-07-16
JP2024037713A (ja) 2024-03-19
AU2023338199B2 (en) 2026-07-16
US12662483B2 (en) 2026-06-23
AR130417A1 (es) 2024-12-04
CL2025000596A1 (es) 2025-04-25
JP2024153948A (ja) 2024-10-29
CA3266872A1 (en) 2024-03-14
WO2024054814A1 (en) 2024-03-14
CR20250077A (es) 2025-04-02
CO2025002467A2 (es) 2025-03-17
US20240116932A1 (en) 2024-04-11
TW202428260A (zh) 2024-07-16
KR20250057022A (ko) 2025-04-28
TWI862146B (zh) 2024-11-11
CN120187720A (zh) 2025-06-20
MX2025002687A (es) 2025-04-02
JP7541606B2 (ja) 2024-08-28
IL319342A (en) 2025-05-01
PE20251400A1 (es) 2025-05-22

Similar Documents

Publication Publication Date Title
Huynh et al. Understanding the role of key amino acids in regulation of proline dehydrogenase/proline oxidase (prodh/pox)-dependent apoptosis/autophagy as an approach to targeted cancer therapy
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
Rewcastle et al. Tyrosine kinase inhibitors. 14. Structure− activity relationships for methyl-amino-substituted derivatives of 4-[(3-bromophenyl) amino]-6-(methylamino)-pyrido [3, 4-d] pyrimidine (pd 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the egf family of growth factors
Wu et al. Synthesis and screening of 3-MA derivatives for autophagy inhibitors
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
EP1079826B1 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
JP2005531488A (ja) 甲状腺癌を処置するためのegf受容体阻害剤
Lv et al. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
UY27370A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células y métodos para su utilización
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
NZ592608A (en) Benzoxazole kinase inhibitors and methods of use
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
DOP2025000054A (es) Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
JOP20240258A1 (ar) مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها
ECSP066767A (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
Buchdunger et al. 4, 5-bis (4-fluoroanilino) phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
Ma et al. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors
Sophonnithiprasert et al. B-AP15 inhibited colon cancer cell proliferation by decreasing CDK6, Cyclin A, Cyclin E, c-Myc, and VEGF gene expression
US20240366536A1 (en) Modulators of a potassium channel and of trpv1 channel and uses thereof